Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis
Authors' conclusion
Over half of US adults with obesity or overweight who initiated tirzepatide were adherent (PDC ≥ 80%) and had a favourable persistence profile during a 6-month follow-up period. Persistent users achieved clinically meaningful weight reduction and numerical reductions in most cardiometabolic risk factors.
Study context
- Population
- US commercially insured adults with ≥1 tirzepatide prescription claim for obesity/overweight without T2D, November 2023–June 2024, ≥12 months pre-index and ≥6 months post-index continuous enrollment (Healthcare Integrated Research Database (HIRD)); mean age 46 years, 73% femaleinitiated tirzepatide
- Participants
- 22,512 participants
- Exposure
- GLP-1 RA naïve vs Switched from GLP-1 RA
- Outcome
- Adherence (PDC ≥80%) and persistence
- Follow-up
- 6-month follow-up
Methodological detailsobservational, administrative claims and electronic health records, descriptive analyses
- Observational
- Administrative claims and electronic health records
- Descriptive analyses
Main finding
As reported in the abstract
6-month follow-up
Adherent (PDC ≥80%)
55%
n = 12 292
Persistent
68%
n = 15 208
Observational data: associations, not effects.
Further findings
≥1 obesity-related complication at baseline
- ≥1 obesity-related complication (most frequent: dyslipidaemia, hypertension, anxiety)
- 91% (n = 20 554)
Mean weight reduction among persistent individuals with pre- and post-index measurements · 6-month follow-up
- Clinically meaningful mean weight reduction (n = 808)
- 10.5%
- Body weight reduction, GLP-naïve subgroup
- 12.0%
- Numerical reductions in most cardiometabolic risk factors
Original publication
Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis. Diabetes Obes Metab. Published 10 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →